The Latest Cardiac and Vascular News
First Patient Enrollment in AGILITY Study Begins Investigations of Safety and Effectiveness of BD Vascular Covered Stent for Treatment of PAD FRANKLIN LAKES, N.J., March 4, 2024 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company,…
SiteRite™ 9 Ultrasound System Delivers Enhanced Image Quality and Vessel Assessment Tools to Aid in First Attempt IV Insertion Success FRANKLIN LAKES, N.J., Nov. 30, 2023 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today…
BD 2025 Strategic Investments Driving Growth and Advancing Innovation; Company Raises Mid-point of Revenue and Adjusted EPS Guidance Ranges Revenue of $4.8 billion increased 1.5% as reported and 4.1% on a currency-neutral basis Revenue from base business (which excludes COVID-only diagnostic testing) grew 6.0% as reported, 8.7% currency-neutral GAAP and adjusted diluted EPS from continuing operations of $1.53 and $2.86, […]
FRANKLIN LAKES, N.J., Feb. 15, 2023 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced that the company has been named to America’s Best Large Employers List 2023 by Forbes, furthering its progress against the company’s environmental, social and governance (ESG) strategy. “This recognition is a reflection of our continued commitment to […]
Execution of BD 2025 Strategy Delivering Consistent and Durable Performance Revenue of $4.6 billion decreased 2.8% as reported and increased 1.7% on a currency-neutral basis Revenue from base business (which excludes COVID-only diagnostic testing) grew 0.4% as reported, 5.2% currency-neutral GAAP and adjusted diluted EPS from continuing operations of $1.70 and $2.98, respectively Company raises full-year revenue and adjusted EPS […]
Execution of BD 2025 Strategy Driving Consistent Durable Growth Q4 revenue from continuing operations of $4.8 billion decreased 1.8% as reported and increased 2.3% on a currency-neutral basis Q4 revenue performance driven by base revenue growth of 4.2% as reported, 8.6% currency-neutral Q4 GAAP and adjusted diluted EPS from continuing operations of $0.92 and $2.75, respectively FY22 revenue from continuing […]
Mike Garrison Named EVP and President, Medical segment Rick Byrd Named EVP and President, Interventional segment FRANKLIN LAKES, N.J., Aug. 25, 2022 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of two senior leaders to segment president roles. Michael (Mike) Garrison has been named executive vice president (EVP) and president […]
FRANKLIN LAKES, N.J., Aug. 8, 2022 /PRNewswire/ — Becton, Dickinson and Company (NYSE: BDX) (the “Company” or “BD“) today announced that it has commenced tender offers to purchase for cash the debt securities issued by the Company listed in the table below (collectively, the “Securities” and each a “series“). Up to an Aggregate Offer Cap of $500,000,000 Aggregate […]
Revenue from continuing operations of $4.6 billion increased 0.7% as reported and 3.8% on currency-neutral basis Revenue from continuing operations driven by base revenue growth of 6.0% as reported, 9.3% currency-neutral Worldwide COVID-only testing revenues of $76 million declined from $300 million in the prior year GAAP diluted EPS from continuing operations of $1.28; adjusted diluted EPS from continuing operations of $2.66 Company […]
Revenue of $5.0 billion increased 2.1% as reported and 3.9% on currency-neutral basis Revenue driven by base revenue growth of 8.2% as reported, 10.2% currency-neutral, partially offset by decline in worldwide COVID-only testing revenues to $214 million from $474 million in the prior year GAAP diluted EPS of $1.50; adjusted diluted EPS of $3.18 Company raises mid-point of revenue and adjusted EPS guidance […]
